<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <script src='echarts.min-4.8.0.js'></script>
        <script src='echarts-wordcloud.min.js'></script>
    </head>
    <body>
        <style>
            html, body, #main {
                width: 100%;
                height: 100%;
                margin: 0;
            }
        </style>
        <div id='main'></div>
        <script>
            var chart = echarts.init(document.getElementById('main'));
            var keywords = {"Isatis tinctoria":1,
"Antioxidant activity":1,
"Biological activity":1,
"Cytotoxicity":2,
"Phenolic profile":1,
"HNF4-α":1,
"NKX2-1 mutation":1,
"TTF-1":3,
"hypermethylation":1,
"non-TRU type":1,
"Biomarkers":2,
"FFPE tissue":1,
"Mass spectrometry":1,
"Proteomics":2,
"Thyroid cancer":27,
"BRAF(V600E)":1,
"DNA repair":1,
"Papillary thyroid cancer":9,
"Prognosis":11,
"laparoscopic":1,
"lasso technique":1,
"pancreatectomy":1,
"perioperative outcomes":1,
"ATA guidelines":1,
"Bethesda system":1,
"Lymph node metastasis":3,
"Papillary thyroid carcinoma":18,
"Ultrasonography":8,
"15q22 locus":1,
"SMAD3":1,
"downstream targets":1,
"functional variants":1,
"Anterior branch":1,
"Extralaryngeal branching":1,
"Intraoperative neuromonitoring":1,
"Motor function":1,
"Recurrent laryngeal nerve":2,
"Thyroidectomy":10,
"Aggressive histology":1,
"Micropapillary thyroid cancer":1,
"Minimal extrathyroidal extension":1,
"PTC":3,
"Tumor diameter":1,
"Asia":1,
"Follicular variant of papillary thyroid carcinoma":1,
"NIFTP":3,
"shear wave elastography":1,
"thyroid nodule":9,
"ultrasound":6,
"Carcinoma, papillary follicular/pathology":1,
"Consensus":1,
"Humans":1,
"Observer variation":1,
"Scoring system":2,
"Thyroid cancer, papillary":1,
"Thyroid neoplasms":7,
"BRAF V600E and RET/PTC":1,
"LIMD2":1,
"Metastases":1,
"Core needle biopsy":1,
"Meta-analysis":5,
"Safety":2,
"18F-FDG-PET/CT":1,
"PET/CT":1,
"immunotherapy":2,
"lung cancer":1,
"molecular imaging":1,
"oncology: lung":1,
"thyroiditis":1,
"National Lung Screening Trial":1,
"computed tomography":1,
"screening":1,
"Hurthle cell carcinoma":1,
"NAB2-STAT6":1,
"STAT6":1,
"dedifferentiated solitary fibrous tumor":1,
"follicular carcinoma":1,
"malignant solitary fibrous tumor":1,
"metastasis":7,
"sarcoma":1,
"thyroid":11,
"clinical pathway":1,
"efficacy":1,
"nurse satisfaction":1,
"standardization":1,
"PRISM-R2":1,
"Quality of life":1,
"Suffering":1,
"Supportive care need":1,
"fine-needle aspiration":7,
"intraocular":1,
"thyroid medullary carcinoma":1,
"transscleral":1,
"Bethesda category":1,
"thyroid malignancy":2,
"FOXP4":1,
"Invasion":6,
"Proliferation":4,
"circMYO9B":1,
"miR-4316":1,
"ERα":1,
"ERβ":1,
"Sorafenib":4,
"VDR":1,
"Vitamin D metabolites":1,
"cDtboc":1,
"Early oral feeding":1,
"Gastrectomy":1,
"Multicenter randomized controlled trial":1,
"Postoperative hospital stay":1,
"SPECT/CT":1,
"parallax error":1,
"parathyroid scintigraphy":1,
"pinhole collimator":1,
"thyroid scintigraphy":1,
"fine needle aspiration":2,
"papillary carcinoma":3,
"thyroglossal duct cyst":1,
"Fine-needle aspiration biopsy":2,
"Thyroid nodules":3,
"Thyroid ultrasound":1,
"Thyroid Imaging Reporting and Data System (TIRADS)":1,
"atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS)":1,
"cancer":6,
"ongoing risk stratification":1,
"thyroid cancer in paediatric age":1,
"Breast cancer":5,
"Disease-free survival":1,
"Lymphocyte-to-monocyte ratio":2,
"Overall survival":1,
"Septic arthritis":1,
"Sternoclavicular joint":1,
"Tracheostomy complications":1,
"ASCL1, achaete-scute homolog like 1":1,
"FFPE, formalin-fixed paraffin-embedded section":1,
"NF1B, nuclear factor 1B":1,
"SCLC, small cell lung cancer":1,
"TTF-1, thyroid transcription factor 1":1,
"neuroendocrine differentiation":1,
"CD10":1,
"adenomatous goitre":1,
"anaplastic thyroid carcinoma":2,
"immunohistochemistry":4,
"thyroid tumour":1,
"Migration":2,
"circZFR":1,
"Compartment-oriented neck dissection":1,
"Medullary thyroid carcinoma":2,
"Node recurrence":1,
"Soft tissue infiltrate recurrence":1,
"AKT":1,
"PPP2R2A":1,
"miR-222":1,
"Epac":1,
"PKA":1,
"PRKAR1A":1,
"Rap1":1,
"follicular thyroid cancer":1,
"AXL":1,
"MTC":1,
"mTOR":2,
"miR-144":1,
"miR-34a":1,
"LRP4":1,
"MMP11":1,
"linc01561":1,
"miR-145-5p":1,
"mixOmics":1,
"Diagnostic":1,
"Fold change":1,
"MiRNA-221":1,
"MiRNA-222":1,
"mortality":3,
"trend":1,
"CTV = clinical target volume":1,
"IMRT = intensity-modulated radiation therapy":1,
"IORT = intraoperative radiotherapy":1,
"MESCC":1,
"MESCC = metastatic epidural spinal cord compression":1,
"OAR = organ at risk":1,
"PRISM = prognostic index for spinal metastases":1,
"PTV = planning target volume":1,
"RPA = recursive partitioning analysis":1,
"RT = radiation therapy":1,
"SBRT = stereotactic body radiotherapy":1,
"decompressive surgery":1,
"oncology":1,
"postoperative spine SBRT":1,
"re-irradiation":1,
"Liver cancer":1,
"Liver cancer stem cell":1,
"Probenecid":1,
"Self-renewal":1,
"Tranilast":1,
"Transient receptor potential vanilloid-type 2 channel":1,
"microRNA-608":1,
"polymorphism":1,
"susceptibility":1,
"Diffuse sclerosing variant":1,
"Disease-specific survival":1,
"Tall cell variant":1,
"demography":1,
"reoperation":1,
"survival":5,
"Angiogenesis":2,
"HDAC9":1,
"Triple negative breast cancer":1,
"microRNA":1,
"Epidemiology":1,
"Geriatric":2,
"NSQIP":1,
"Older patients":1,
"Surgery":3,
"Dysthyroid eye disease":1,
"Glucocortoid-resistant":1,
"Graves’ orbitopathy":1,
"Rituximab":1,
"Neuroblastoma":1,
"Paediatric cancer treatment":1,
"Paediatric isolation":1,
"Radioiodine therapy":2,
"Thyroid cancer treatment":1,
"Thyrotoxicosis":1,
"adolescents":1,
"children":1,
"incidence":2,
"young adults":1,
"RAS mutations":1,
"lobectomy":2,
"surveillance":1,
"Preoperative":1,
"Thyroglobulin":2,
"Aggressive variants":1,
"Genetics":1,
"Persistent":1,
"Progression":3,
"TERT":1,
"Cytology":3,
"Diagnosis":3,
"Negative":1,
"LNM":1,
"incomplete treatment":1,
"thermal ablation":1,
"Hypothyroidism":1,
"hemithyroidectomy":1,
"Malignancy":1,
"Thy":1,
"China":2,
"Life expectancy":1,
"ER ɑ":1,
"RNF168":1,
"transcription":1,
"external validation":1,
"metastatic epidural spinal cord compression":1,
"predictive factors":1,
"prospective study":1,
"Follow-up":2,
"Papillary follicular/pathology":1,
"Reclassification":1,
"atrophy":1,
"clinical characteristics":1,
"itching":1,
"vulvar lichen sclerosus":1,
"ARO":1,
"ascorbic acid":1,
"catalase":1,
"juglone":1,
"superoxide dismutase":1,
"Non-small cell lung cancer":1,
"SEER":1,
"CXCR5 + CD8+ T cells":1,
"PD-1":1,
"Foxp3":1,
"autophagy":3,
"chemotherapy":1,
"miR-125b":1,
"biomarker":1,
"exosomes":1,
"pancreatic cancer":1,
"zinc transporter ZIP4":1,
"Estrogen":1,
"Nuclear factor erythroid 2-related factor 2 (NRF2)":1,
"Resveratrol":1,
"UDP-Glucuronosyltransferase (UGT)":1,
"Cancer-associated fibroblasts":1,
"Lymph node":1,
"Risk factor":2,
"MAL2":1,
"MiR-129":1,
"Papillary thyroid carcinoma (PTC)":1,
"Tumor growth":1,
"MEG3":1,
"Thyroid carcinoma(131)I radioactivity":1,
"lncRNA":2,
"miR-182":1,
"Copy number amplification":1,
"LINC01061":1,
"Long noncoding RNA":1,
"Cell cycle":1,
"Cyclin D":1,
"Cyclin E":1,
"G(1)/S transition":1,
"Adverse events":1,
"Hypertension":1,
"Lenvatinib":3,
"Patient Safety":1,
"Protein kinase inhibitors":1,
"Proteinuria":1,
"chyle":1,
"neck dissection":2,
"Cancer stem cells":2,
"Reactive oxygen species":1,
"Sphere formation":1,
"CT scan":1,
"Ionising radiation":1,
"Risk":1,
"Young population":1,
"Adrenal cortex":1,
"Adrenal medulla":1,
"Adrenal rest tumor":1,
"Ectopia":2,
"Ectopic ACTH syndrome":1,
"Pheochromocytoma":2,
"DNA damage avoidance":1,
"Human MutT homologue 1":1,
"Prox1-as1":1,
"BRAF inhibitor":1,
"BRAF mutation":2,
"Melanoma":2,
"Vemurafenib":1,
"Blindness":1,
"Diplopia":1,
"ICT":1,
"Thrombosis":1,
"Insulin resistance":1,
"Metabolic syndrome":1,
"Parasitic nodule":1,
"Parathyroid glands":1,
"Parathyromatosis":1,
"Thyroid dysgenesis":1,
"Thyroid gland":1,
"Esophagus":1,
"Gastrointestinal tract":1,
"Heterotopia":1,
"Intestine":1,
"Stomach":1,
"131I":1,
"classifications":1,
"differentiated thyroid cancer":3,
"radioiodine refractory":1,
"IMRT":1,
"concurrent chemoradiation therapy":1,
"TIRADS":1,
"imaging":1,
"multinodular goiter":1,
"PI3 kinase pathway":1,
"follicular thyroid carcinoma":1,
"poorly differentiated thyroid carcinoma":1,
"refractory thyroid cancer":1,
"targeted therapy":2,
"low- and intermediate-ATA risk":1,
"thyroid lobectomy":1,
"thyroid-stimulating hormone":1,
"classic papillary thyroid cancer":1,
"dynamic risk stratification":1,
"nonexcellent response":1,
"risk factors":1,
"Iodine radioisotopes":2,
"Neoplasm invasiveness":2,
"Radiotherapy":2,
"interprofessional care":1,
"interprofessional team":1,
"phenomenology":1,
"(PubMED CID: 11707110)":1,
"50922675)":1,
"Binimetinib (PubMED CID: 10288191)":1,
"Catalytic spine":1,
"Cobimetanib (PubMED CID: 16222096)":1,
"Dabrafenib: (PubMED CID: 44462760)":1,
"Encorafenib: (PubMED CID":1,
"K/E/D/D":1,
"LY3009120 (PubMED CID: 71721540)":1,
"Lifirafenib: (PubMED CID:89670174)":1,
"PLX7904: (PubMED CID: 901169945)":1,
"Protein kinase inhibitor classification":1,
"Protein kinase structure":1,
"Sorafenib: (PubMED CID: 216239)":1,
"Targeted cancer therapy":1,
"Trametinib":2,
"Vemurafenib: (PubMED CID: 42611257)":1,
"neovascularization":1,
"tyrosine kinase receptor inhibitors":1,
"vascular mimicry":1,
"vasculogenesis":1,
"apoptosis":1,
"scinderin":1,
"long non-coding RNA":1,
"mRNA":1,
"TPC-1":1,
"bleomycin":1,
"polarization":1,
"tumor-associated macrophages":1,
"cisplatin":2,
"octreotide":1,
"side population":1,
"thyroid carcinoma":4,
"doxorubicin":1,
"tolerance":1,
"toxicity":1,
"Breast tissue":1,
"Human intervention studies":1,
"Isoflavones":1,
"Observational studies":1,
"Safety evaluation":1,
"Thyroid hormone system":1,
"actin skeleton":1,
"ginsenoside Rg3":1,
"Deiodination":1,
"FT(3)/FT(4)":1,
"Refractory":1,
"Metastatic lymph node ratio":1,
"SDC4":1,
"Wnt/β-catenin signaling pathway":1,
"epithelial mesenchymal transition":1,
"NFκB":1,
"matrix metalloproteinases (MMP)-11":1,
"p65":1,
"Carotid artery pulsation":1,
"Diagnostic performance":1,
"Elasticity contrast index":1,
"Elastography":1,
"Histology":1,
"Hyperthyroidism":2,
"Hypophysitis":1,
"Immune checkpoint blockade":1,
"Immune-related adverse events":1,
"Macroadenoma":1,
"Pituitary adenoma":2,
"FNAB":1,
"cancer biology":1,
"copy number alteration":1,
"genomics":1,
"human":1,
"human biology":1,
"medicine":1,
"prostate cancer":1,
"Glycolysis":1,
"HCC":1,
"HIF-1α":1,
"Hypoxia":1,
"Yes-associated protein (YAP)":1,
"bilateral axillo-breast approach":1,
"comparison":1,
"transoral":1,
"Circ-ITCH":1,
"Circular RNA":1,
"Indeterminate cytology":1,
"Molecular testing":1,
"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features":1,
"Synovial sarcoma":1,
"pathology":3,
"therapy":1,
"Primary tumor score":1,
"depth of tumor invasion":1,
"esophageal squamous cell carcinoma":1,
"tumor length":2,
"bevacizumab":1,
"carboplatin":1,
"pemetrexed":1,
"BRAF V600E":1,
"TERTp mutation":1,
"Crohn’s disease":1,
"Immunosuppressant":1,
"Inflammatory bowel diseases":1,
"Ulcerative colitis":1,
"Dabrafenib":1,
"Radioactive iodine-refractory disease":1,
"Tyrosine kinase inhibitors":2,
"subacute thyroiditis":1,
"ACTH = adrenocorticotropic hormone":1,
"FSH = follicle-stimulating hormone":1,
"LH = luteinizing hormone":1,
"PA = pituitary adenoma":1,
"PY = person-year":1,
"TSH = thyroid-stimulating hormone":1,
"VIS = visual impairment scale":1,
"natural history":1,
"nonfunctioning":1,
"observation":1,
"pituitary surgery":1,
"SDHB":1,
"catecholamines":1,
"genetic susceptibility":1,
"metastatic paraganglioma":1,
"paraganglioma":1,
"Parathyroid lesions":1,
"Parathyroidectomy":1,
"Thyroid incidentalomas":1,
"Carcinoma, hepatocellular":1,
"Licartin":1,
"Liver transplantation":1,
"Radioimmunotherapy":1,
"Retrograde dissection":1,
"Surgical anatomy":1,
"Surgical technique":1,
"Advanced disease":1,
"Calcitonin":1,
"Carcinoembryonic antigen":1,
"Tumor marker":1,
"telecytopathology":1,
"neoplasms":1,
"net survival":1,
"population-based":1,
"registries":1,
"survival analysis":1,
"Anlotinib":1,
"NSCLC":2,
"STS":1,
"Tyrosine kinase inhibitor":1,
"VEGFR":1,
"hedgehog proteins":1,
"Inflammatory index":1,
"Tumor-node-metastasis staging system":1,
"ATC":1,
"BRAF":1,
"Genetically engineered mice":1,
"SLC7A5":1,
"locoregional recurrence":1,
"adrenal carcinoma":1,
"neuroendocrine carcinoma":1,
"pituitary carcinoma":1,
"Esophageal cancer":1,
"FDG PET/CT":1,
"Peritumoral halo layer":1,
"Reliability test":1,
"Tumor segmentation":1,
"metabolomics":1,
"FOXO3a":1,
"Hashimoto's thyroiditis":1,
"differentiated thyroid carcinoma":1,
"sirtuin1":1,
"vitamin D":1,
"vitamin D receptor":1,
"OPNa":1,
"matrix calcification":1,
"osteopontin":1,
"psammoma bodies":1,
"Breast neoplasms":1,
"Hypoxia-inducible factor 1":1,
"Smad3 protein":1,
"Transforming growth factor beta1":1,
"age":1,
"clinical features":1,
"lateral lymph node metastasis":1,
"Follicular adenoma":1,
"neck mass":1,
"squamous cell carcinoma":1,
"Adequacy and accuracy of FNAC thyroid":1,
"Bethesda system of thyroid cytology reporting":1,
"fine-needle aspiration cytology":1,
"ultrasound of thyroid":1,
"ultrasound-guided fine-needle aspiration of thyroid tumors":1,
"Atorvastatin":1,
"MDA-MB-231":1,
"ultrastructural changes":1,
"Cancer therapy":1,
"Multikinase inhibitors":1,
"SIRT1":1,
"acetylation":1,
"epigenetic modulation":1,
"secretory organs":1,
"Metazoa":1,
"RAD51":1,
"archaea":1,
"evolution":1,
"network":1,
"cancer epidemiology":1,
"cancer registry data":1,
"health inequalities":1,
"social class":1,
"socioeconomic factors":1,
"Accessory lacrimal gland":1,
"Adenocarcinoma":1,
"Adenocarcinoma not otherwise specified":1,
"Carcinoma":1,
"Eyelid":1,
"Gland of Wolfring":1,
"Lacrimal gland":1,
"mammary analog secretory carcinoma":1,
"salivary gland":1,
"Cushing’s syndrome":1,
"Mitotane":1,
"adrenocortical carcinoma":1,
"mitotanemia":1,
"ADAM10":1,
"Gastric cancer":1,
"lncRNA SNHG1":1,
"miR-140":1,
"3D Organoids":1,
"3D, 3-dimensional":1,
"5-Fluorouracil":1,
"5FU, 5-fluorouracil":1,
"AV, autophagy vesicle":1,
"CD44":1,
"CD44H, high expression of CD44":1,
"CQ, chloroquine":1,
"DMEM, Dulbecco’s modified Eagle medium":1,
"EMT, epithelial-mesenchymal transition":1,
"ESCC, esophageal squamous cell carcinoma":1,
"FBS, fetal bovine serum":1,
"H&amp":1,
"E, hematoxylin and eosin":1,
"IC50, half maximal inhibitory concentration":1,
"IHC, immunohistochemistry":1,
"LC3, light chain 3":1,
"OPSCC, oropharyngeal squamous cell carcinoma":1,
"PI, propidium iodide":1,
"SCCs, squamous cell carcinomas":1,
"TE11R, 5-fluorouracil–resistant derivative of TE11":1,
"Biphasic synovial sarcoma":1,
"Molecular biology":1,
"mandible":1,
"metastatic tumours":1,
"tibia":1,
"germ cell tumours":1,
"ovary":1,
"strumal carcinoid":1,
"Biomarkers, tumor":1,
"Croatia":1,
"Thyroid hormones":1,
"ALK rearrangement":1,
"Lung adenocarcinoma":1,
"ROS1 rearrangement":1,
"breast":1,
"thyroid transcription factor-1":1,
"EGFR expression":1,
"EGFR mutation":1            };
            var data = [];
            for (var name in keywords) {
                data.push({
                    name: name,
                    value: Math.sqrt(keywords[name])
                })
            }
            var maskImage = new Image();
            var option = {
	             title: {
                text: '2018年9月论文keyword词云'
            },
                series: [ {
                    type: 'wordCloud',
                    sizeRange: [15, 100],
                    rotationRange: [-90, 90],
                    rotationStep: 45,
                    gridSize: 2,
                    shape: 'pentagon',
                    maskImage: maskImage,
                    drawOutOfBound: false,
                    textStyle: {
                        normal: {
                            color: function () {
                                return 'rgb(' + [
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160)
                                ].join(',') + ')';
                            }
                        },
                        emphasis: {
                            color: 'red'
                        }
                    },
                    data: data.sort(function (a, b) {
                        return b.value  - a.value;
                    })
                } ]
            };
            maskImage.onload = function () {
                option.series[0].maskImage
                chart.setOption(option);
            }
            maskImage.src = 'data:image/png;base64,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';
            window.onresize = function () {
                chart.resize();
            }
        </script>
    </body>
</html>
